ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Apyx Medical Corporation Showcases New Data and Treatment Insights at the Renuvion® Users’ Summit

Shaping the Future of Aesthetic Treatments with Advanced Medical Technology

Apyx® Medical Corporation (NASDAQ: APYX) (the “Apyx Medical”; “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce the Renuvion Users’ Summit is taking place in Las Vegas from April 12-13, 2024.

The Renuvion Users’ Summit brings together a diverse group of dedicated professionals in cosmetic and plastic surgery from 13 countries to share new research, applications, and clinical experiences with the Company’s Renuvion technology. The insights and innovation shared at the Renuvion Users’ Summit will help medical professionals provide the highest level of care for their patients seeking solutions to improve the appearance of loose skin through body contouring and other procedures.

The Renuvion Users’ Summit will feature 27 key opinion leader speakers who bring a deep knowledge and understanding of the Renuvion technology and how it can be used to enhance outcomes for patients. New data and research will be presented, with a focus on body contouring, fat transfer and the safety of Renuvion, including during the following presentations:

  • The Renuvion Effect: Using Ultrasound to Measure Tissue Contraction
  • Scarless Mastopexy: Pearls of Using the Renuvion Technology
  • Enhanced Fat Graft Viability Following Renuvion Pretreatment
  • Renuvion in High-Definition Liposuction: The European Concept of Beauty
  • The Back/Bra Roll: A Consistent and Reproducible Treatment with Renuvion

“The Renuvion Users’ Summit brings together some of the most brilliant minds in the cosmetic surgery market, all united with a single goal – to provide their patients with best-in-class care. It is designed to support our surgeon customers by providing them with access to new insights and research related to the use of our Renuvion technology,” said Charlie Goodwin, President, and CEO of Apyx Medical Corporation.

“Renuvion has transformed the lives of thousands of patients seeking solutions for loose skin worldwide,” said Dr. Paul G. Ruff, board-certified plastic surgeon and clinical research investigator for Apyx Medical. “The clinical data showcasing Renuvion's safety and efficacy is unmatched in the category, and the knowledge shared at the Renuvion Users’ Summit will continue to advance the science and ultimately benefit patients everywhere.”

Renuvion represents the pinnacle of propriety helium plasma and radiofrequency technology, designed to achieve tissue contraction by addressing the problem of loose skin directly at the source, ultimately providing patients with next level body contouring results. With six new FDA clearances and three exclusive indications, including the only post-liposuction use and subcutaneous tissue contraction clearances, Renuvion continues to set new standards in safety and performance.

About Apyx Medical Corporation

Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.